CA2326690A1 - The process for manufacturing topical ophthalmic preparations without systemic effects - Google Patents

The process for manufacturing topical ophthalmic preparations without systemic effects Download PDF

Info

Publication number
CA2326690A1
CA2326690A1 CA002326690A CA2326690A CA2326690A1 CA 2326690 A1 CA2326690 A1 CA 2326690A1 CA 002326690 A CA002326690 A CA 002326690A CA 2326690 A CA2326690 A CA 2326690A CA 2326690 A1 CA2326690 A1 CA 2326690A1
Authority
CA
Canada
Prior art keywords
drug
timolol
systemic
polymer
topical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002326690A
Other languages
English (en)
French (fr)
Inventor
Bakulesh Mafatlal Khamar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2326690A1 publication Critical patent/CA2326690A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA002326690A 1999-02-03 2000-02-02 The process for manufacturing topical ophthalmic preparations without systemic effects Abandoned CA2326690A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN90BO1999 IN185228B (el) 1999-02-03 1999-02-03
IN90/BOM/99 1999-02-03
PCT/IN2000/000008 WO2000049990A2 (en) 1999-02-03 2000-02-02 The process for manufacturing topical ophthalmic preparations without systemic effects

Publications (1)

Publication Number Publication Date
CA2326690A1 true CA2326690A1 (en) 2000-08-31

Family

ID=11077485

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002326690A Abandoned CA2326690A1 (en) 1999-02-03 2000-02-02 The process for manufacturing topical ophthalmic preparations without systemic effects

Country Status (11)

Country Link
EP (1) EP1139970A2 (el)
AP (1) AP2000001977A0 (el)
AU (1) AU4429100A (el)
BR (1) BR0004530A (el)
CA (1) CA2326690A1 (el)
EA (1) EA200000918A1 (el)
ID (1) ID28121A (el)
IL (1) IL138824A0 (el)
IN (1) IN185228B (el)
WO (1) WO2000049990A2 (el)
ZA (1) ZA200006252B (el)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011061252A2 (en) 2009-11-18 2011-05-26 Galderma Research & Development Combination therapy for treating or preventing an inflammatory skin disorder
EP2388007A1 (en) 2003-05-27 2011-11-23 Galderma Pharma S.A. Compounds, formulations, and methods for treating or preventing rosacea
EP2481412A1 (en) 2004-05-25 2012-08-01 Galderma Pharma S.A. Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
WO2013001073A1 (en) 2011-06-29 2013-01-03 Galderma Research & Development A new stable anesthetic composition for reducing skin reactions

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8858961B2 (en) 2000-07-14 2014-10-14 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
AU2005220199B2 (en) * 2000-07-14 2007-03-08 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
NZ521185A (en) * 2000-07-14 2005-02-25 Allergan Inc Compositions containing alpha-2-adrenergic agonist components
DE10132876A1 (de) * 2001-07-06 2003-01-30 Medproject Pharma Entwicklungs Zweiphasige, tropfbare Hydrogele zur Anwendung am Auge
WO2014127243A1 (en) 2013-02-15 2014-08-21 Allergan, Inc. Sustained drug delivery implant
WO2014150899A1 (en) * 2013-03-15 2014-09-25 Chapin Matthew J Topical ophthalmic formulations for treating migraine
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
US11382909B2 (en) 2014-09-05 2022-07-12 Sydnexis, Inc. Ophthalmic composition
US11052094B2 (en) 2015-05-29 2021-07-06 Sydnexis, Inc. D2O stabilized pharmaceutical formulations
GB202110420D0 (en) * 2021-07-20 2021-09-01 Rosemont Pharmaceuticals Ltd Liquid pharmaceutical composition of clonidine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6056684B2 (ja) * 1977-11-07 1985-12-11 東興薬品工業株式会社 点眼剤
DD294174A5 (de) * 1990-05-04 1991-09-26 Sigrid Keipert Ophthalmika mit retardwirkung und ein neues verfahren zu ihrer herstellung
FR2678832B1 (fr) * 1991-07-10 1995-03-17 Europhta Sa Laboratoire Nouvelles compositions ophtalmiques a resorption amelioree et leurs procedes de preparation.
FR2679773A1 (fr) * 1991-07-30 1993-02-05 Merck Sharp & Dohme Preparation ophtalmique contenant un agent osmotique acceptable antimicrobien.
DE19614823A1 (de) * 1996-04-15 1997-10-16 Mann Gerhard Chem Pharm Fab Ophthalmische Zusammensetzung mit verlängerter Verweilzeit am Auge

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2388007A1 (en) 2003-05-27 2011-11-23 Galderma Pharma S.A. Compounds, formulations, and methods for treating or preventing rosacea
EP2815748A1 (en) 2003-05-27 2014-12-24 Galderma Pharma S.A. Compounds, formulations, and methods for treating or preventing rosacea
EP2481412A1 (en) 2004-05-25 2012-08-01 Galderma Pharma S.A. Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
WO2011061252A2 (en) 2009-11-18 2011-05-26 Galderma Research & Development Combination therapy for treating or preventing an inflammatory skin disorder
EP2329849A1 (en) 2009-11-18 2011-06-08 Galderma Research & Development Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
WO2013001073A1 (en) 2011-06-29 2013-01-03 Galderma Research & Development A new stable anesthetic composition for reducing skin reactions

Also Published As

Publication number Publication date
IN185228B (el) 2000-12-09
WO2000049990A3 (en) 2001-07-26
AU4429100A (en) 2000-09-14
ZA200006252B (en) 2001-11-29
EA200000918A1 (ru) 2001-10-22
IL138824A0 (en) 2001-10-31
ID28121A (id) 2001-05-03
EP1139970A2 (en) 2001-10-10
WO2000049990A2 (en) 2000-08-31
AP2000001977A0 (en) 2000-12-31
BR0004530A (pt) 2001-04-03

Similar Documents

Publication Publication Date Title
EP0538313B1 (en) Topical ophthalmic suspensions
EP1028707B1 (en) Sustained release ophthalmic compositions containing water soluble medicaments
US5710182A (en) Ophthalmic composition
EP2588078B1 (fr) Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur
CN102046149B (zh) 稳定的眼药制剂
EP2109442B1 (en) Ophthalmic compositions containing a synergistic combination of three polymers
CA2326690A1 (en) The process for manufacturing topical ophthalmic preparations without systemic effects
US5795913A (en) Ophthalmic composition
Rathore et al. Preparation and characterization of timolol maleate ocular films
WO2011018800A2 (en) A novel in-situ gel forming solution for ocular drug delivery
Chang et al. Relative effectiveness of prodrug and viscous solution approaches in maximizing the ratio of ocular to systemic absorption of topically applied timolol
EP1189595B1 (en) Ophthalmic compositions in form of aqueous gels
US20110003816A1 (en) Ophthalmic composition
MXPA00009715A (en) The process for manufacturing topical ophthalmic preparations without systemic effects
JP2013129604A (ja) 緑内障治療薬を含有する徐放性フィルム製剤
EP1137407B1 (en) Ophthalmic formulation comprising a beta blocker and carbopol
EP4230193A1 (en) Ophthalmic pharmaceutical composition
Herrero-Vanrell et al. Comparison of the in vitro tolerance and in vivo efficacy of traditional timolol maleate eye drops versus new formulations with bioadhesive polymers
TW200301128A (en) Ophthalmic composition for the treatment of glaucoma, ocular hypertension, ocular ischemia and related disorders

Legal Events

Date Code Title Description
FZDE Discontinued